Commentary on Hsiue et al: Cost savings and data limitations of new cancer drug studies.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 126, doi. 10.1177/1740774520907668
- By:
- Publication type:
- Article
Works matching IS 17407745 AND DT 2020 AND VI 17 AND IP 2
Results: 15
1
2
The costs of cancer drugs.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
3
Estimated costs of pivotal trials for U.S. Food and Drug Administration–approved cancer drugs, 2015–2017.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 119, doi. 10.1177/1740774520907609
- By:
- Publication type:
- Article
4
Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patients.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 184, doi. 10.1177/1740774520901514
- By:
- Publication type:
- Article
5
Role of health plan administrative claims data in participant recruitment for pragmatic clinical trials: An Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) example.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 212, doi. 10.1177/1740774520902989
- By:
- Publication type:
- Article
6
Information growth for sequential monitoring of clinical trials with a stepped wedge cluster randomized design and unknown intracluster correlation.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 176, doi. 10.1177/1740774520901488
- By:
- Publication type:
- Article
7
Non-inferiority designs comparing placebo to a proven therapy for childhood pneumonia in low-resource settings.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 129, doi. 10.1177/1740774519888460
- By:
- Publication type:
- Article
8
Using a Delphi survey to gain an international consensus on the challenges of conducting trials with adults with intellectual disabilities.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 138, doi. 10.1177/1740774519887168
- By:
- Publication type:
- Article
9
Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews.
- Published in:
- 2020
- By:
- Publication type:
- Letter
10
Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 202, doi. 10.1177/1740774519895966
- By:
- Publication type:
- Article
11
Effect of telephone calls from a centralized coordinating center on participant retention in a randomized clinical trial.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 195, doi. 10.1177/1740774519894229
- By:
- Publication type:
- Article
12
To attend, or not to attend: Examining caregiver intentions and study compliance in a pediatric, randomized controlled trial.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 223, doi. 10.1177/1740774519893307
- By:
- Publication type:
- Article
13
How do clinical research coordinators learn Good Clinical Practice? A mixed-methods study of factors that predict uptake of knowledge.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 166, doi. 10.1177/1740774519893301
- By:
- Publication type:
- Article
14
Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 147, doi. 10.1177/1740774519890146
- By:
- Publication type:
- Article
15
Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
- Published in:
- Clinical Trials, 2020, v. 17, n. 2, p. 157, doi. 10.1177/1740774519890145
- By:
- Publication type:
- Article